These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 8546909)

  • 1. Randomised trial for the prevention of delayed emesis in patients receiving high-dose cisplatin.
    Matsui K; Fukuoka M; Takada M; Kusunoki Y; Yana T; Tamura K; Yoshida T; Iida K; Hirashima T; Tsukada H; Ushijima S; Miyawaki H; Masuda N
    Br J Cancer; 1996 Jan; 73(2):217-21. PubMed ID: 8546909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Control of high-dose-cisplatin-induced emesis with an all-oral three-drug antiemetic regimen.
    Hesketh PJ; Roman A; Hesketh AM; Perez EA; Edelman M; Gandara DR
    Support Care Cancer; 2000 Jan; 8(1):46-8. PubMed ID: 10650897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy of three 5-HT3 antagonists (granisetron, ondansetron, and tropisetron) plus dexamethasone for the prevention of cisplatin-induced acute emesis: a randomized crossover study.
    Chua DT; Sham JS; Kwong DL; Kwok CC; Yue A; Foo YC; Chan R
    Am J Clin Oncol; 2000 Apr; 23(2):185-91. PubMed ID: 10776982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral granisetron with or without methylprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting induced by cisplatin-based chemotherapy. A prospective randomized trial.
    Gebbia V; Testa A; Valenza R; Cannata G; Tirrito ML; Gebbia N
    Cancer; 1995 Nov; 76(10):1821-8. PubMed ID: 8625054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone.
    Campos D; Pereira JR; Reinhardt RR; Carracedo C; Poli S; Vogel C; Martinez-Cedillo J; Erazo A; Wittreich J; Eriksson LO; Carides AD; Gertz BJ
    J Clin Oncol; 2001 Mar; 19(6):1759-67. PubMed ID: 11251007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved control of high-dose-cisplatin-induced acute emesis with the addition of prochlorperazine to granisetron/dexamethasone.
    Hesketh PJ; Gandara DR; Hesketh AM; Edelman M; Webber LM; McManus M; Hainsworth JD
    Cancer J Sci Am; 1997; 3(3):180-3. PubMed ID: 9161784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of oral 5-HT3-receptor antagonists and low-dose oral metoclopramide plus i.m. dexamethasone for the prevention of delayed emesis in head and neck cancer patients receiving high-dose cisplatin.
    Mantovani G; Macciò A; Curreli L; Lampis B; Ghiani M; Bianchi A; Contu P
    Oncol Rep; 1998; 5(1):273-80. PubMed ID: 9458381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dexamethasone improves the efficacy of granisetron in the first 24 h following high-dose cisplatin chemotherapy.
    Latreille J; Stewart D; Laberge F; Hoskins P; Rusthoven J; McMurtrie E; Warr D; Yelle L; Walde D; Shepherd F
    Support Care Cancer; 1995 Sep; 3(5):307-12. PubMed ID: 8520877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized cross-over trial of granisetron and dexamethasone versus granisetron alone: the role of dexamethasone on day 1 in the control of cisplatin-induced delayed emesis.
    Sekine I; Nishiwaki Y; Kakinuma R; Kubota K; Hojo F; Matsumoto T; Ohmatsu H; Yokozaki M; Kodama T
    Jpn J Clin Oncol; 1996 Jun; 26(3):164-8. PubMed ID: 8656557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind, randomised, parallel study comparing intravenous dolasetron plus dexamethasone and intravenous dolasetron alone for the management of fractionated cisplatin-related nausea and vomiting.
    Fauser AA; Pizzocaro G; Schueller J; Khayat D; Wilkinson P
    Support Care Cancer; 2000 Jan; 8(1):49-54. PubMed ID: 10650898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Italian Group of Antiemetic Research.
    Ann Oncol; 1995 Oct; 6(8):805-10. PubMed ID: 8589019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomised comparison of ondansetron plus dexamethasone with dexamethasone alone for the control of delayed cisplatin-induced emesis.
    Tsukada H; Hirose T; Yokoyama A; Kurita Y
    Eur J Cancer; 2001 Dec; 37(18):2398-404. PubMed ID: 11720834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral granisetron alone and in combination with dexamethasone: a double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. The Granisetron Study Group.
    Heron JF; Goedhals L; Jordaan JP; Cunningham J; Cedar E
    Ann Oncol; 1994 Sep; 5(7):579-4. PubMed ID: 7993831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial high anti-emetic efficacy of granisetron with dexamethasone is not maintained over repeated cycles.
    de Wit R; van den Berg H; Burghouts J; Nortier J; Slee P; Rodenburg C; Keizer J; Fonteyn M; Verweij J; Wils J
    Br J Cancer; 1998 May; 77(9):1487-91. PubMed ID: 9652766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
    Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone.
    Kris MG; Pendergrass KB; Navari RM; Grote TH; Nelson AM; Thomas V; Ferguson BB; Allman DS; Pizzo BA; Baker TW; Fernando IJ; Chernoff SB
    J Clin Oncol; 1997 May; 15(5):2135-8. PubMed ID: 9164228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group.
    Latreille J; Pater J; Johnston D; Laberge F; Stewart D; Rusthoven J; Hoskins P; Findlay B; McMurtrie E; Yelle L; Williams C; Walde D; Ernst S; Dhaliwal H; Warr D; Shepherd F; Mee D; Nishimura L; Osoba D; Zee B
    J Clin Oncol; 1998 Mar; 16(3):1174-8. PubMed ID: 9508205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group.
    Navari RM; Reinhardt RR; Gralla RJ; Kris MG; Hesketh PJ; Khojasteh A; Kindler H; Grote TH; Pendergrass K; Grunberg SM; Carides AD; Gertz BJ
    N Engl J Med; 1999 Jan; 340(3):190-5. PubMed ID: 9917226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.
    Van Belle S; Lichinitser MR; Navari RM; Garin AM; Decramer ML; Riviere A; Thant M; Brestan E; Bui B; Eldridge K; De Smet M; Michiels N; Reinhardt RR; Carides AD; Evans JK; Gertz BJ
    Cancer; 2002 Jun; 94(11):3032-41. PubMed ID: 12115394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind randomized study comparing intramuscular (i.m.) granisetron with i.m. granisetron plus dexamethasone in the prevention of delayed emesis induced by cisplatin. The Italian Multicenter Study Group.
    Anticancer Drugs; 1999 Jun; 10(5):465-70. PubMed ID: 10477166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.